Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s adjusted earnings and revenue top analysts’ estimates. Exxon Mobil and Chevron are ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

The company has heavily advertised AI features since the latest iPhones were released in September. Revenue rose 10% from a year ago to $9.5 billion. The shift occurs after many brands cut their ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the National Institute for Health and Care Excellence (NICE) said on Friday.

The initial concept to focus on pain-signaling proteins came out of research involving people with a rare hereditary ...

Suki experienced remarkable growth, expanding 4x in only 12 months. This next phase is driven by our latest investments and the expanding opportunities within our addressable market, with technology ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a ...

ServiceNow and Google Cloud announced a major expansion of their partnership to maximize the value of generative AI across ...